Lv1
10 积分 2025-12-11 加入
Reversibility of Dry Eye Deceleration After Topical Cyclosporine 0.05% Withdrawal
20天前
已完结
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
5个月前
已完结
Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
5个月前
已完结
Scleral contact lenses are not optically inferior to corneal lenses
5个月前
已完结
Scleral lenses for correction of irregular astigmatism: advances and limitations
5个月前
已完结
Altered functional connectivity between the default mode network in diabetic retinopathy patients
6个月前
已完结
Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies
6个月前
已完结
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
6个月前
已完结
Comparison of Dry Eye Treatment Outcomes in Patients with or without Autoimmune Disease
6个月前
已完结
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
6个月前
已完结
皖公网安备34019202002308
